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MULTIPLE SCLEROSIS-LIKE LESIONS AND TYPE I INTERFERON SIGNATURE IN A PATIENT WITH RVCL
Retinal vasculopathy with cerebral leukodystrophy (RVCL) is a rare late-onset autosomal dominant systemic microvascular disease due to C-terminal truncation mutations in the three prime repair exonuclease 1 gene, TREX1.
1 Patients present with varying degrees of progressive bilateral vision loss, renal impairment, and neurologic symptoms. Cerebral MRI shows either confluent tumorlike signal alterations or multiple small white matter lesions. 2 , 3 Herein we demonstrate a case of RVCL caused by a novel TREX1 mutation with distinct lesions on cerebral MRI and type I interferon (IFN) activation.
Level of evidence. This case report provides Class IV evidence that chloroquine did not prevent progression in a patient with RVCL caused by a novel TREX1 mutation.
Case report. In 2012, a 39-year-old Caucasian man presented to us with the presumed diagnosis of multiple sclerosis (MS) based on multiple white matter lesions on cerebral MRI with partial rim enhancement after administration of gadolinium (Gd) (figure, A and B). Clinically he had mild weakness and hypesthesia of the left arm and face accompanied by mild pulsating headache. CSF examination including oligoclonal bands was normal. Further laboratory investigations revealed normocytic anemia, antinuclear antibodies (1:200), and anti-C1q autoantibodies. High-dose glucocorticoids (GC) improved clinical symptoms but had no effect on Gd enhancement of the cerebral lesions.
His medical history was remarkable for arterial hypertension and proteinuria since the age of 30 years. A renal biopsy demonstrated a thickening of the glomerular basement membrane but no evidence of vasculitis. Subsequently he developed retinal microangiopathy with progressive loss of visual acuity (75%) in the left eye (figure, F) . He experienced intermittent episodes of arthralgia and mild pulsating headache for several years. Renal as well as retinal and neurologic abnormalities were regarded as unrelated diseases.
His mother had meningioma and Parkinson disease, while his father died of pleural mesothelioma at the age of 69 without clinical evidence of RVCL. His younger brother died in early childhood from an unknown brain tumor.
Prompted by the clinical phenotype with the involvement of microvessels in the brain, retina, and kidney, we presumed a hereditary endotheliopathy. Genetic testing of the TREX1 gene on chromosome 3p21.31 identified a heterozygous novel T deletion (c.822delT) leading to a shift of the reading frame and premature termination of protein translation at amino acid 275 (p.Pro275Glnfs*2), thus confirming the clinical diagnosis of RVCL. The patient's mother tested negative for the respective mutation. Furthermore, despite the absence of increased IFN-a in serum, we identified an upregulation of type I IFN-inducible genes by quantitative reverse transcription PCR of peripheral blood mononuclear cells consistent with innate immune activation (figure, G and supplemental data). Due to its known inhibitory IFN-a effects, therapy with chloroquine was started; however, the patient progressed clinically and on MRI.
Discussion. This case expands the phenotypic spectrum of patients with TREX1 mutations. Cerebral MRI abnormalities in RVCL can be misdiagnosed as MS, Binswanger disease, CADASIL, multi-infarct dementia, systemic lupus erythematosus (SLE) with vasculitis, and brain tumor. 2, 3 In our patient, MS was initially suggested by the presence of periventricular white matter lesions with partial Gd enhancement, which demonstrated dissemination in time and space on follow-up MRI ( figure, D) . However, additional detailed MRI analysis revealed features unusual for MS-related imaging patterns: (1) Gd enhancement was patchy and did not respond to GC; (2) small focal signal hypointensities on MRI and CT hyperattenuations were noted in the lesions, indicating calcifications (figure, C); and (3) there was evidence of increased iron depositions in the substantia nigra and nucleus ruber, which might be a distinct feature of RVCL (figure E).
In RVCL, TREX1 mutations alter the perinuclear localization of the TREX1 protein while the exonuclease activity remains intact, indicating a critical functional role of the subcellular localization of TREX1.
1 It is interesting that C-terminal truncating TREX1 mutations have also been described in patients with SLE. 4 Mutations that disrupt the enzymatic exonuclease function of the TREX1 protein may cause familial chilblain lupus or AicardiGoutières syndrome (AGS), a leukencephalopathy with elevated IFN-a levels in the CSF and characteristic calcifications on cerebral MRI beginning in early childhood. 5 Both disorders are characterized by signs of inflammation and autoimmunity.
Recently, a distinct type I IFN signature in the blood of patients with mutation-proven AGS and chilblain lupus has been described, identifying type I IFN as a key factor in the pathogenesis of the inflammatory phenotype. 6, 7 The observed upregulation of type I IFN-dependent genes, the formation of autoantibodies, and the history of intermittent arthralgia suggest an overlapping autoimmune component in our patient, which has not been reported so far for RVCL. Whether the type I IFN signature is a distinct feature of RVCL has to be further investigated. However, these findings suggest that patients with RVCL may therapeutically benefit from IFN-a blockade. 
